Home

Post event on demand access to recorded presentations will be available to all attendees 5 working days from the end date of the event.

overview

SMi proudly presents the 4th Annual Ophthalmic Drugs Conference taking place on the 22nd-23rd of November 2021, in London.

The global ophthalmic drug market is forecast to surpass $60 billion USD by 2025 with increasing focus from the industry on alternative delivery approaches and improving the effectiveness of the current repertoire of drugs in order to grow away from intravitreal injections and other surgical approaches to ocular therapy. With 50% of the global population predicted to have complications in their sight within the next few decades, ophthalmic medicine is set to become one of the biggest industries in pharmaceuticals.

As Europe’s leading Ophthalmic Drugs conference, we will explore new discoveries in the treatment of ocular disease, innovations in combination technologies, and the utterly unique challenges that are faced in the treatment of one of the most complex organs in the body.

This two-day agenda will offer peer-to-peer networking opportunities with leaders in the ophthalmic sphere, from Heads of Drug Development and Senior Directors of Ophthalmology, all the way to academic forerunners in the research into ocular therapy.

We look forward to welcoming you to the conference in November.

Early registration is strongly advised to avoid disappointment.

 

  • GAIN insight into the latest treatments for Glaucoma and Dry-Eye Disease from Aerie Pharmaceuticals
  • EXAMINE the challenges of designing the right drug for topical drug delivery to the retina with Ocuterra Therapeutics
  • UNDERSTAND the advancements in treatments for inherited retinal diseases from ProQR
  • EXPLORE the design and characteristics of a durable local ocular formulation with forwardvue pharma
  • DISCUSS patient centricity as a driver for drug delivery innovation in ophthalmology with Roche
  • DISCOVER a novel target for Geographic Atrophy and Diabetic Retinopathy with InflammX Therapeutics
  • REVIEW the hidden and unmet clinical need of Diabetic Macular Ischemia with Boehringer Ingelheim
  • RECEIVE key updates on ocular gene therapy from SparingVision
  • UNCOVER the clinical development and regulatory landscape for ophthalmic products in the UK and Europe from Bayer

 

- CEOs, CMOs and Researchers from pharmaceutical companies involved in ocular drug development, in addition to biotechnologies involved in ocular drug delivery research.

- Heads and VPs of Retinal Health, Ocular Therapy, Medical Safety, and Ophthalmology.

- Professors, Senior Lecturers, and Specialists in Ocular biology and immunology, and clinical pharmaceuticals.

Aerie Pharmaceuticals; Alcon Management SA; Boehringer Ingelheim Biopharmaceuticals Gmbh; Carl Zeiss AG; Centro de Oftamologia Barraquer; Experimentica Ltd; Eyenuk; Global Ophthamology R&D, Santen Inc, USA; Graybug Vision Inc; iVeena; Iveric Bio; Kingston University; Kingston University London; Medicines & Healthcare products Regulatory Agency (MHRA); Medivis; MedPharm Ltd; MHRA; Nanoptima Ltd; Newcastle University; Novartis Pharmaceutical inc; Ophthalmic Drugs 2019; Ophthalmology Times Europe; Optceutics Ltd; ProMed Pharma, LLC; ProQR Therapeutics; RAFARM S.A. Pharmaceuticals; Roche; Roche Products Limited; Santen UK; Spark Therapeutics; Thea Open Innovation; Topivert; twoXAR; UCL Institute of Ophthalmology; UCL School of Pharmacy and UCL Institute of Ophthalmology; University of Oxford; University of Reading; University of Strathclyde;

Conference programme

8:00 Registration & Coffee

9:00 Chair's Opening Remarks

Mitchell De Long

Mitchell De Long, Vice President, Chemistry, Aerie Pharmaceuticals
View Bio

9:10 Port Delivery System with Ranibizumab: A surgery, device, drug combination product

Jaya Chidambaram

Jaya Chidambaram, Associate Clinical Director, Roche Genentech
View Bio

• PDS technology and procedures
• Clinical outcomes of the Archway Phase 3 Trial in nAMD
• Unique aspects of development of a combination product
 

9:50 Design and characteristics of a sustained release local ocular formulation of carboxyamidotriazole, a safe and effective antiangeogenic with a novel mechanism of action

Alan Franklin

Alan Franklin, CEO, ForwardVue Pharma
View Bio

• Established systemic safety in cancer trials
• Safety and efficacy in ocular preclinical models
• Novel mechanism of action, ORAI1 inhibition
• Design and characteristics of durable local ocular formulation

10:30 New mechanism of action anti-inflammatory analgesic for the treatment of ocular pain

Damon Smith

Damon Smith, CEO, TALLC Inc

• TA-A001: a new CB2 receptor agonist for the treatment of ocular pain and inflammation
• SmartCelle technology to deliver TA-A001 to the eye
• SmartCelle TA-001 in preclinical models of acute pain, corneal surgery, uveitis and retinopathy
 

11:10 Morning Coffee

11:40 For Topical Drug Delivery to the Retina – Design the Right Drug

Kerrie Brady

Kerrie Brady, Chief Executive Officer, OcuTerra Therapeutics
View Bio

• “Purpose engineering” to design OTT166 selective integrin antagonist
• Review of preclinical research demonstrating delivery and activity of OTT166 with eye drop dosing
• Clinical research results with OTT166 in diabetic retinal disease and wAMD to date, plans for Phase 2
 

12:20 Preclinical large animal AMD models

Simon Kaja

Simon Kaja, Chief Scientific Officer & Vice-President, Americas, Experimentica Ltd
View Bio

13:00 From the trabecular meshwork to the retina – Ophthalmological research at Aerie

Mitchell De Long

Mitchell De Long, Vice President, Chemistry, Aerie Pharmaceuticals
View Bio

• Update on Aerie’s ROCK & combination treatments for glaucoma, including our 2021 approval in the EU and ongoing clinical trials in Japan
• Aerie’s ongoing clinical and preclinical studies for retinal diseases, including the clinical programs for AR-1105, and AR-13503
• Introduction to AR-15512, a clinical candidate for Dry Eye disease
• Future outlook for glaucoma treatment and for long-term ocular dosing for the treatment of ocular disease
 

13:40 Networking Lunch

14:40 Novel upstream target inhibiting the NLRP3 inflammasome in geographic atrophy and diabetic retinopathy

Brian Levy

Brian Levy, CEO, InflammX Therapeutics
View Bio

• Disruptive and transformative potential for disease modification
• Xiflam - orally administered small molecule cx43 hemichannel inhibitor
• MOA and Xiflam efficacy demonstrated in phenotypical models of disease (GA, DR)
• Target Cx43 hemichannel is present in human tissue with disease (AMD and DR)
• MOA confirmed in ex vivo human cadaver retinas with diseases of interest
• In Phase 2B clinical studies by Q4/20

15:20 Diabetic Macular Ischaemia: A hidden unmet medical need

Victor Chong

Victor Chong, Global Head of Medicine, Retinal Health, Boehringer Ingelheim Pharma GmbH & Co. KG
View Bio

• Diabetic retinopathy is a leading cause of working age blindness
• With the advances of vitrectomy and anti-VEGF, why do patients continue to go blind?
• Diabetic macular ischaemia can now be measured
• Why not have more companies working on that?

15:50 Childhood Myopia: a pediatric eye disease at an epidemic scale

Simon Chandler

Simon Chandler, Executive Director, Clinical Development, Allergan Ltd

• Utilising pharmacologic interventions to treat refractive errors
• Therapeutic overview: Product candidates in Phase II – III at Nevakar
• Our approach: treating the progression Near-sightedness with Atropine
 

16:00 Afternoon Tea

16:30 Ocular tolerability and formulation toxicity in drug development

Virginia Calder

Virginia Calder, Reader in Ocular Immunology, UCL Institute of Ophthalmology
View Bio

• In vivo and In vitro models for tolerability and toxicity
• Characterising the physical and biological stability of new ocular therapies
• The in vivo toxicity of Brolucizumab in the macula
• Advances in cationic emulsions to moderate dry eye disease

17:10 Patient centricity as a driver for drug delivery innovation in ophthalmology

Gregoire Schwach

Gregoire Schwach, Leader Ocular and Drug Delivery, PTD Biologics Europe, Roche
View Bio

• Patient centric pharmaceutical drug product design
• Ocular delivery challenges
• Treatment efficacy improvement opportunities
• Ocular long-acting drug product approaches
 

17:50 Chair’s Closing Remarks and Close of Day One

Mitchell De Long

Mitchell De Long, Vice President, Chemistry, Aerie Pharmaceuticals
View Bio

8:30 Registration & Coffee

9:00 Chair's Opening Remarks

Mitchell De Long

Mitchell De Long, Vice President, Chemistry, Aerie Pharmaceuticals
View Bio

9:10 Ocular Gene Therapy

Daniel  Chung

Daniel Chung, Chief Medical Officer, SparingVision

• The basic tenets of ocular gene therapy
     o What we have learned
     o What we still need to know
• Update on current ocular gene therapy
     o Current genotypes under investigation
     o Who’s in clinical trials
     o What’s on the market
• The future of ocular gene therapy
     o Delivery systems
     o Gene agnostic approaches
 

9:50 Development of Lumevoq gene therapy in Leber Hereditary Optic Neuropathy (LHON) subjects

Magali Taiel

Magali Taiel, Chief Medical Officer , Gensight-Biologic
View Bio

• Key clinical development steps
• EMA & FDA regulatory pathways
• Results of pivotal studies
• Key learnings and next steps
 

10:30 Morning Coffee

11:00 Advancements in treatments for inherited retinal diseases

Aniz Girach

Aniz Girach, Chief Medical Officer, ProQR Therapeutics
View Bio

• Antisense oligonucleotides have shown much promise in Ph1/2 Clinical Trials in LCA10 and Usher’s Syndrome
• Recent Interim Analyses in key trials have shed much light on mechanism of action of antisense oligonucleotides
• Overview of the data available from clinical trials
 

11:40 Panel Discussion: Genetic therapy for inherited retinal diseases

  • Latest trends in genetic therapy for Inherited Retinal Diseases
  • Clinical Trial Endpoints for Inherited Retinal Diseases
  • Regulatory guidance/thresholds for Clinical Trial Endpoints in Inherited Retinal Diseases
     
  • Aniz Girach

    Aniz Girach, Chief Medical Officer, ProQR Therapeutics
    View Bio

    Daniel  Chung

    Daniel Chung, Chief Medical Officer, SparingVision

    Magali Taiel

    Magali Taiel, Chief Medical Officer , Gensight-Biologic
    View Bio

    12:20 Non-viral gene therapy for the prolonged delivery of proteins in the eye

    Francine Behar-Cohen

    Francine Behar-Cohen, Chief Innovation Officer, Eyevensys
    View Bio

    • Eyevensys develops a non-viral gene therapy combined therapy to deliver plasmids encoding any therapeutic proteins in the ciliary muscle
    • A simple procedure using a disposable device and an external application has been developed
    • Sustained protein production in the eye has been demonstrated
    • Phase I/II study has demonstrated the safety of the procedure- Phase II studies ongoing in Europe and in the US
     

    13:00 Networking Lunch

    14:00 Ocular delivery of small molecules and biologics using long-acting injectable photocrosslinked implants

    Thakur Raghu Raj Singh

    Thakur Raghu Raj Singh, Reader in Pharmaceutics, Founder and CTO Re-Vana Therapeutics, Chair for Ocular Delivery Focus Group, Queen's University Belfast
    View Bio

  • Intravitreal injections and eye drops offer little ocular bioavailability - leading to frequent administrations and poor patient compliance
  • Innovative solutions are needed to address the unmet need in ocular delivery of molecules
  • Understanding current challenges and engineering new delivery systems
  • Insight into novel photo-crosslinked in situ depot forming and preformed implants
  • 14:40 Nanomaterials for posterior segment drug delivery

    Laurence  Fitzhenry

    Laurence Fitzhenry, Lecturer & Project Coordinator, ORBITAL-ITN
    View Bio

    • Outline of the ORBITAL network
    • Specific examples of nano/micro technologies for ophthalmic delivery
    • Challenges associated with posterior segment delivery
    • Outline of the projects and focus of the ORBITAL-ITN

    15:20 Recent advancements in the formulation and delivery of APIs to the ocular surface and anterior segment of the eye

    Ali  Athab Al-Kinani

    Ali Athab Al-Kinani, Senior Lecturer in Clinical Pharmaceutics, Kingston University
    View Bio

    • Glaucoma and cataract are the two leading causes for blindness worldwide, whereas dry eye is the most widely treated eye condition
    • Conventional dosage forms, mainly in the form of eye drops and surgery are still widely used to manage these conditions
    • Conventional treatment offers poor efficacy, whilst surgery is associated with complications and is not readily available to patients in developing countries
    • There is a need for innovative delivery technologies to overcome these issues
     

    16:00 Afternoon Tea

    16:30 Innovative pathways and compounds for improved therapies of retinal vascular disorders (DME, wet AMD, RVO) : Beyond anti-VEGF

    Grace C Chang

    Grace C Chang, Chief Medical Officer, Oxurion NV

    • Oxurion at the forefront with 2 global Phase 2 clinical programs :
           o Update from Phase 2 evaluating THR-149 (a plasma kallikrein inhibitor) for treatment of DME-patients, suboptimal responding to previous anti-VEGF
           o Update from Phase 2 evaluating THR-687 (a pan-RGD integrin antagonist) for treatment of DME, with fast follow development potential in wet AMD and RVO
     

    17:10 Clinical development and regulatory landscape for ophthalmic products in UK and Europe

    Peter Morgan Warren

    Peter Morgan Warren, Ophthalmology specialist & pharmaceutical physician; Senior Medical Advisor , Bayer

    • Overview of current regulatory guidance relating to ophthalmic medicines
    • Update on devices and combination approaches for novel ocular therapeutics
    • Special considerations for advanced therapies, rare diseases and paediatric medicines
     

    17:50 Chair’s Closing Remarks and Close of Day Two

    Mitchell De Long

    Mitchell De Long, Vice President, Chemistry, Aerie Pharmaceuticals
    View Bio

    +

    FEATURED SPEAKERS

    Alan Franklin

    Alan Franklin

    CEO, ForwardVue Pharma
    Aniz Girach

    Aniz Girach

    Chief Medical Officer, ProQR Therapeutics
    Brian Levy

    Brian Levy

    CEO, InflammX Therapeutics
    Damon Smith

    Damon Smith

    CEO, TALLC Inc
    Daniel  Chung

    Daniel Chung

    Chief Medical Officer, SparingVision
    Francine Behar-Cohen

    Francine Behar-Cohen

    Chief Innovation Officer, Eyevensys
    Gregoire Schwach

    Gregoire Schwach

    Leader Ocular and Drug Delivery, PTD Biologics Europe, Roche
    Ian Catchpole

    Ian Catchpole

    Chief Scientific Officer, Horama
    Jaya Chidambaram

    Jaya Chidambaram

    Associate Clinical Director, Roche Genentech
    Kerrie Brady

    Kerrie Brady

    Chief Executive Officer, OcuTerra Therapeutics
    Laurence  Fitzhenry

    Laurence Fitzhenry

    Lecturer & Project Coordinator, ORBITAL-ITN
    Magali Taiel

    Magali Taiel

    Chief Medical Officer , Gensight-Biologic
    Mitchell De Long

    Mitchell De Long

    Vice President, Chemistry, Aerie Pharmaceuticals
    Simon Chandler

    Simon Chandler

    Executive Director, Clinical Development, Allergan Ltd
    Simon Kaja

    Simon Kaja

    Chief Scientific Officer & Vice-President, Americas, Experimentica Ltd
    Thakur Raghu Raj Singh

    Thakur Raghu Raj Singh

    Reader in Pharmaceutics, Founder and CTO Re-Vana Therapeutics, Chair for Ocular Delivery Focus Group, Queen's University Belfast
    Victor Chong

    Victor Chong

    Global Head of Medicine, Retinal Health, Boehringer Ingelheim Pharma GmbH & Co. KG
    Virginia Calder

    Virginia Calder

    Reader in Ocular Immunology, UCL Institute of Ophthalmology

    Alan Franklin

    CEO, ForwardVue Pharma
    Alan Franklin

    During Retinal Fellowship at University of Iowa, Dr. Franklin secured both HEED and HEED-Knapp scholarships. His research work on an anti-vascular agent as a candidate to treat retinal diseases such as diabetic retinopathy and age-related macular degeneration was awarded the best research project by an ophthalmic physician in training at the 1999 Association of University Professors in Ophthalmology meeting. Dr. Franklin has continued his interest and progress in the treatment of diabetic retinopathy and age-related macular degeneration (AMD) in his vitreoretinal practice. He is founder and CEO of ForwardVue Pharma, and also consults to develop retinal surgical visualization.

    Ali Athab Al-Kinani

    Senior Lecturer in Clinical Pharmaceutics, Kingston University
    Ali  Athab Al-Kinani

    Ali Athab Al-Kinani is a senior lecturer in Clinical Pharmaceutics at Kingston University, London. He leads research groups in ophthalmic drug delivery where his research is tackling aging related eye diseases such as cataract and glaucoma. Furthermore, Ali’s research is looking at improving drugs’ bioavailability on the ocular and anterior segment of the eye using novel delivery systems and formulations.

    His high standard research was acknowledged nationally and internationally where he was an awardee of several national and international research awards such as the American Association of Pharmaceutical Scientists (AAPS).

     

    Aniz Girach

    Chief Medical Officer, ProQR Therapeutics
    Aniz Girach

    Aniz Girach, qualified as an Ophthalmologist (specialty in Retina), and worked in Cambridge (UK).
    After having spent 11 years in the NHS, he joined the pharmaceutical industry with Eli Lilly, focusing on retinal diseases. He has in total 24 years industry experience in roles with Merck (as their Global Head of Ophthalmology) and Alcon, where he was Vice President of Clinical Development, and ThromboGenics, where he was the Global Head of Ophthalmology/Chief Medical Officer overseeing the development and approval of Ocriplasmin (Jetrea)—a first in class biologic therapy for retinal disease. In his role as Chief Medical Officer at Nightstar Therapeutics, he led and oversaw the development of their gene therapy programmes for inherited retinal diseases, prior to their acquisition by Biogen. In addition to being an Honorary Professor at Wills Eye Hospital, Philadelphia, USA, he is currently the Chief Medical Officer at ProQR Therapeutics, leading the development of RNA therapies for inherited retinal diseases.
    He is a member of 3 Scientific Advisory Boards for international ophthalmic organizations currently, and reviewer for 5 peer-reviewed journals, including Eye and IOVS. He has edited 4 books and published over 70 abstracts/manuscripts in peer-reviewed journals in Ophthalmology, with numerous invited lectures at national/international ophthalmology meetings.
    His special interests are Medical Retina, Vitreomacular Interface Abnormalities and Gene/RNA Therapy for inherited retinal diseases.

    Brian Levy

    CEO, InflammX Therapeutics
    Brian Levy

    CEO of Ocunexus Therapeutics a clinical stage company developing products targeting the innate NLRP3 inflammasome in pathological autoinflammation
    Chief Medical Officer Aerie Pharmaceuticals - 2 Rho Kinase Inhibitors for lowering of IOP in Glaucoma Approved and commercialized.
    VP of R&D and Chief Medical Officer Bausch & Lomb 15 years 3 NDA’s;
    Retisert - the first approved intravitreal Drug Delivery System for Posterior Uveitis
    Zylet - topical steroid/antibiotic for ophthalmic infection/inflammation
    Bezivance - 4th generation fluoroquinolone for ocular bacterial infection
    Multiple device approvals; IOL’s, Cataract, Retinal, Refractive Surgical Equipment, Contact Lenses
    Associate Professor, Ophthalmology, CPMC San Francisco, Private Practice Toronto, Clinical investigator consultant to the ophthalmic industry. 60 peer reviewed publications presented globally major meetings. O.D. at UC Berkeley, M.Sc. Comparative Ocular Physiology University Waterloo. On boards of 3 startups.
     

    Damon Smith

    CEO, TALLC Inc
    Damon Smith

    Daniel Chung

    Chief Medical Officer, SparingVision
    Daniel  Chung

    Francine Behar-Cohen

    Chief Innovation Officer, Eyevensys
    Francine Behar-Cohen

    Francine Behar-Cohen is a retina specialist at Cochin Hospital, Paris University hospital. She heads an Inserm team of basic and clinician scientists since 2001. As an expert for ANSES (the French Agency for Food, Environmental and Occupational Health & Safety), she was president of the GT_LED1 for the evaluation of the ocular toxicity of LED (2010) of 3D (2014) and for all LED applications (2018). From 2013 to 2017, she was the chairwoman of the Jules Gonin Eye hospital. She created Optis France, in 1999 that became Eyegate Pharma for ocular iontophoresis, Eyevensys in 2012, for non-viral gene therapy for retinal diseases. She serves as Chief Innovation Officer in Eyevensys.

    Grace C Chang

    Chief Medical Officer, Oxurion NV
    Grace C Chang

    Gregoire Schwach

    Leader Ocular and Drug Delivery, PTD Biologics Europe, Roche
    Gregoire Schwach

    Grégoire Schwach joined Roche in Basel (Switzerland) in 2015, as head of drug delivery in Pharmaceutical Development and Supplies (Biologics Europe). As the leader of the ocular and drug delivery team since 2019, Grégoire carries also CMC Drug Product responsibilities for the ophthalmology pipeline. His team is taking care of the design and execution of the formulation and drug product development, including manufacturing process development. His current focus areas are within stable liquid formulations of biologics for intravitreal injection, sustained release technologies, and high concentration formulations of biologics. Before joining Roche, he worked in several positions in pharmaceutical drug development at Ferring Pharmaceuticals A/S (Copenhagen, Denmark), and as head of polymer development at Phusis Matériaux Biorésorbables (Grenoble, France).
    Grégoire is educated in Chemical Engineering from INSA Rouen in France. He specialized in polymers for therapeutic applications with a doctorate at the University of Montpellier in the team of Prof. Michel Vert. He moved on as a postdoc fellow at the University of Geneva (Switzerland) in the group of Prof. Robert Gurny. During his career, Grégoire co-supervised several Postdocs, PhDs and Master students, participated in two EU-funded consortium projects, and is the (co-)author of 20+ scientific publications and (co-)inventor of 11 patent families.
     

    Ian Catchpole

    Chief Scientific Officer, Horama
    Ian Catchpole

    Jaya Chidambaram

    Associate Clinical Director, Roche Genentech
    Jaya Chidambaram

    Dr. Jaya Chidambaram, BSc(Hons), MBBS, MRCOphth, PhD

    Jaya is an Associate Medical Director in Roche Genentech and is the medical lead for the global Port Delivery System phase 3/3b clinical trial. She received her medical degree in Guy’s, Kings’ and St. Thomas’s Medical School, London, and her PhD from the London School of Hygiene and Tropical Medicine. After her ophthalmology specialist registrar training in London, she completed a Fellowship in Paediatric Ophthalmology at Great Ormond Street Hospital and worked as a Consultant Ophthalmologist in Manchester Royal Eye Hospital before joining the Roche Genentech ophthalmology clinical development team in 2019.
     

    Kerrie Brady

    Chief Executive Officer, OcuTerra Therapeutics
    Kerrie Brady

    Kerrie Brady is CEO and President (Designee) of OcuTerra Therapeutics Inc., a clinical stage ophthalmology company developing a novel eye drop, OTT166, designed to treat diabetic retinal disease. This first-in-class, highly disruptive treatment has the potential to treat diabetic retinal disease earlier and more efficiently, with established clinical data showing safety and demonstrating biological activity.
    Prior to joining OcuTerra Kerrie was co-founder, Chief Business Officer and Executive Vice President, Corporate Strategy at Centrexion Therapeutics. She is an experienced international biopharmaceutical leader with a successful 30-year track record. Her focus has been founding entrepreneurial ventures and working with biopharma companies and research organizations on value creation for new and emerging technologies using her broad, cross-discipline, expertise in business, science and product development. Prior to founding Centrexion, Kerrie was co-founder and Chief Operations Officer for Vallinex Inc., Co-founder and Chief Operations Officer for Arcion Therapeutics Inc., and Founder and Chief Executive Officer of Traxion Therapeutics, Inc.
    Leading up to her entrepreneurial career Kerrie worked in both public and private biotechnology companies in business development and operations roles leveraging her experience in product management and regulatory affairs obtained working for major pharmaceutical companies. Kerrie holds a Bachelor of Pharmacy from Victorian College of Pharmacy, an MBA from the University of Melbourne and an M.S. in Biopharmaceuticals from the University of New South Wales.
     

    Laurence Fitzhenry

    Lecturer & Project Coordinator, ORBITAL-ITN
    Laurence  Fitzhenry

    Dr. Laurence Fitzhenry is a Lecturer in Chemistry at the Department of Science, Waterford Institute of Technology and Principal Investigator of the Ocular Therapeutics Research Group (OTRG) at the PMBRC.
    He received his PhD in polymer and analytical chemistry from WIT in 2011, where he conducted his postdoctoral research on the development of contact lenses for the controlled release of pharmaceutical actives.
    Laurence is the project co-ordinator for the MSCA-funded ORBITAL-ITN, a global consortium focused on training researchers in the development of innovative strategies for posterior segment drug delivery to the eye.

    Magali Taiel

    Chief Medical Officer , Gensight-Biologic
    Magali Taiel

    Dr. Taiel completed her doctorate in Medicine with board certified in Ophthalmology from Lariboisiere Saint Louis University, Paris, France, in 1993, and her Associate Professor degree in 1998. Dr Taiel completed her internship at academic Paris hospitals, was an Associate Professor of Ophthalmology, served as an Ophthalmology Department Head, and ran Surgical and Medical Ophthalmology private practice. After 13 years of Ophthalmology public and private practice, Dr Taiel has been engaged in the Pharma Industry for 20 years; she brings extensive experience and expertise in drug clinical development, gene therapy, and medical affairs. She started her carrier at Servier company headquarter, and then worked in Ophthalmology area at Pfizer for several years; she then held international and management positions in various therapeutic areas, including both technical and supervision duties, at Eli Lilly Company for many years. Then, as VP Clinical Development, she led Clinical Development and Operations, to develop antisense oligonucleotides in Inherited Retinal diseases at ProQR Therapeutics. She then moved to GenSight-Biologics in 2018, to supervise the Medical Department and lead Gene Therapy programs in Inherited Retinal and Neuro-Ophthalmology diseases, as the CMO of the company.
    Dr. Taiel has authored numerous protocols and articles published in peer reviewed journals, and made critical contributions to successful clinical development and launch of many products. She brings extensive years of experience from both academic medicine and pharma industry.

    Mitchell De Long

    Vice President, Chemistry, Aerie Pharmaceuticals
    Mitchell De Long

    Mitchell A. (Mitch) deLong holds the position of vice president, Chemistry at Aerie Pharmaceuticals as well as Adjunct Professor of Chemistry at Duke University. Since Mitch helped to found Aerie as a Duke University spinout in 2005, Aerie has filed 6 INDs and 2 NDAs, with its first FDA approval coming in 2017, and its second less than 18 months later. Aerie has grown from the initial 3-person team to over 300 employees and went public on NASDAQ in 2013. Mitch is lead inventor on over 60 issued US patents, about half of those at Aerie, and has over 100 publications, posters and presentations, including co-chairing all three of SMI’s Ophthalmic Drugs’ Conferences. Mitch earned his PhD in Synthetic Organic and Medicinal Chemistry at Stanford University, and has two other marketed drugs, unrelated to ophthalmology to his credit.

    Peter Morgan Warren

    Ophthalmology specialist & pharmaceutical physician; Senior Medical Advisor , Bayer
    Peter Morgan Warren

    Simon Chandler

    Executive Director, Clinical Development, Allergan Ltd
    Simon Chandler

    Simon Kaja

    Chief Scientific Officer & Vice-President, Americas, Experimentica Ltd
    Simon Kaja

    Dr. Kaja serves as CSO and VP, Americas of Experimentica, a global preclinical CRO specialized in ophthalmic indications.
    Dr. Kaja received his undergraduate degree in Molecular Biology and Biochemistry from Durham University, UK and obtained his Ph.D. in Medicine from Leiden University, The Netherlands. He has held postdoctoral and researcher positions at The University of British Columbia, the University of North Texas Health Science Center at Fort Worth, Bayer, Novo Nordisk, and NeuroSearch. Prior to joining Experimentica, Dr. Kaja served on the faculty of the University of Missouri - Kansas City.
    Dr. Kaja is an internationally recognized expert in ocular drug discovery and development, author of more than 60 peer-reviewed publications, several book chapters and recipient of numerous grants and awards. Dr. Kaja also holds an appointment as Endowed Professor in Ophthalmology at Loyola University Chicago.
     

    Thakur Raghu Raj Singh

    Reader in Pharmaceutics, Founder and CTO Re-Vana Therapeutics, Chair for Ocular Delivery Focus Group, Queen's University Belfast
    Thakur Raghu Raj Singh

    Dr Raj Thakur is a Reader in Pharmaceutics at the School of Pharmacy (SoP), QUB and is the Founder, CTO and Director of Re-Vana Therapeutics. His research interest is in the design and physicochemical characterisation of advanced long-acting biodegradable drug delivery systems including minimally invasive medical devices for localised drug delivery. He is the Chair for Ocular Drug Delivery (OcDD) Focus Group supported by the mission of Controlled Release Society (CRS). He has authored over 160 scientific publications, including 60 full papers, 10 book chapters, five textbooks, several invited talks in national and international conferences and patents. To date, he has secured funding of approx. £5 million research funding.

    Victor Chong

    Global Head of Medicine, Retinal Health, Boehringer Ingelheim Pharma GmbH & Co. KG
    Victor Chong

    Victor Chong, Global Head of Medicine, Retinal Health, Boehringer Ingelheim International GmBH.
     

    Victor Chong is a retinal specialist who is specialized in macular diseases. He is currently the Global Head of Medicine, Retinal Health at Boehringer Ingelheim International GmBH, Germany and Consultant Ophthalmic Surgeon at London Medical and Royal Free Hospital, London. He was the Head of Department at Oxford Eye Hospital and had held senior academic position at Institute of Ophthalmology, London, King’s College, London and Oxford University. He has published 3 books, 18 book chapters and over 150 publications. He is also the academic founder of a device company, aiming to treat intermediate AMD and early DME.
     

    Virginia Calder

    Reader in Ocular Immunology, UCL Institute of Ophthalmology
    Virginia Calder

    Virginia L. Calder, PhD,
    Professor of Ocular Immunology,
    UCL Institute of Ophthalmology,
    London, UK.

    Professor Calder is an immunologist with considerable research experience in inflammatory eye diseases (posterior uveitis, atopic and vernal keratoconjunctivitis). Immunosuppressive drugs can be effective but often have devastating side-effects, especially for the eye, when taken long term. Accessibility of drugs, especially to the back f the eye, and toxicity are also key challenges.
    Professor Calder’s research has investigated underlying immune mechanisms and potential novel therapeutic targets, as well as testing drug efficacy. This involves utilizing relevant experimental models of disease and validating results with clinically well-defined donor specimens. She has considerable expertise in determining the toxicity and therapeutic efficacy of novel compounds in vitro and in vivo, in her research collaborations with Pharma.
     

    Sponsors

    Official Media Partner

    Supporting Media Partners

    Supporters

    Workshops

    Novel Platforms in Ocular Drug Delivery
    Workshop

    Novel Platforms in Ocular Drug Delivery

    Venue To Be Confirmed
    24th November 2021
    London, United Kingdom

    Ophthalmic Drug Delivery Development - Trials and Tribulations
    Workshop

    Ophthalmic Drug Delivery Development - Trials and Tribulations

    Venue To Be Confirmed
    24th November 2021
    London, United Kingdom

    VENUE

    Holiday Inn Kensington Forum

    97 Cromwell Road , London, United Kingdom

    Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington. 

    The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow. 

    This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel. 

    In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event. 

    So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee. 

    A number of our clients have been approached by third party organisations offering to book hotel rooms. We would advise that you do not book through them as they are not representing the SMi Group. SMi Group books all hotel rooms directly. If you are approached by a third party organisation then please contact us before making any bookings. If you have already booked a hotel room using a third party organisation, we would highly recommend contacting the hotel you were booked into to ensure a booking has been made for you. We would also advise you to please check the terms and conditions of the booking carefully.
    HOTEL BOOKING FORM

    SPEAKER INTERVIEW WITH VICTOR CHONG, Boehringer Ingelheim Pharma

    Download

    SPEAKER INTERVIEW - ALAN FRANKLIN, CEO, ForwardVue Pharma

    Download

    Chair letter

    Download

    Speaker Interview - MAGALI TAIEL, GENSIGHT-BIOLOGIC

    Download

    Ophthalmic Drugs Infographic

    Download

    William Dallman – Eyenuk, PAST PRESENTATION

    Download

    Virginia L. Calder, PhD, UCL, PAST PRESENTATION

    Download

    Dr Che John Connon , Newcastle University, PAST PRESENTATION

    Download

    AARON C DAUGHERTY, TWOXAR, PAST PRESENTATION

    Download

    Pete Morgan-Warren, MHRA, PAST PRESENTATION

    Download

    Sponsors


    Experimentica

    Sponsors
    https://experimentica.com/

    Experimentica combines expertise in Ophthalmology and preclinical ocular models with state of the art imaging and functional assessment capabilities.

    As a global CRO we work with Pharmaceutical Companies, Biotechs, and Academia. Our solutions bridge the gap between the development of new models and their use in developing clinical applications.



    TALLC Inc.

    Sponsors
    https://tallcinc.com/

    TALLC is a pre-clinical stage biopharmaceutical company developing our new mechanism medicines to treat acute and chronic conditions in the eye.

    Our Mission

    To Improve the Lives of Patients by Inventing and Developing Valuable New Ophthalmic Medicines

    Our Vision

    To be a leading provider of pipeline opportunities in ophthalmics enabling better clinical and commercial outcomes.

    Our Advantage

    Our pipeline of new mechanism synergistic API, enabled for pan-ocular delivery by our SmartCelleTM and AmyloFlexTMdelivery platforms, developed by our expert team of scientist and industry professionals.

    Our Programs

    Largely virtual, the high experienced TALLC team will first focus on SmartCelle TA-A001, a micellar formulation of our novel CB2 receptor specific drug candidate: • As a topically instilled eye drop for the severe pain and inflammation that occurs after cross-linking surgery for keratoconus • As a topical treatment to avoid the pain and inflammation resulting from PRK, LASIK, SMILE and Cataract surgeries • TALLC is also developing extended release formulations of our pipeline candidates for treatment of Dry-Eye Disease, Uveitis, AMD and Glaucoma


    Media Partners


    Eye News

    Official Media Partner
    https://www.eyenews.uk.com/

    Eye News, both in print and online, provides a comprehensive tour of the wide range of current issues facing all eye care professionals. Ever issue is written by key opinion leaders in the field and includes clinical features, commentary, overviews of the key recent academic papers, book reviews and industry news. The magazine boasts a comprehensive training and conference diary in addition to in-depth conference reports and a monthly events enewsletter. The magazine gives a breadth of filtered information on all aspect of ophthalmology specialist and key related issues and subscription is free to readers in the UK. “Time is precious and we pride ourselves at Eye News in the task of scouring the land to secure acknowledged experts to give practical and pragmatic advice, teaching the reader in an entertaining and informative way” Prof Bal Dhillon, Editor, Prof of Clinical Ophthalmology, University of Edinburgh and Hon Consultant Princess Alexandra Eye Pavilion, Edinburgh https://www.eyenews.uk.com/


    ONdrugDelivery Magazine

    Official Media Partner
    http://ondrugdelivery.com

    ONdrugDelivery provides 30,000 readers throughout global pharma/biopharma, with the latest, most pertinent industry information and intelligence about the drug delivery-related ideas, technologies, services and products the sector is developing. Established in 2004, and trusted throughout the industry for its high quality contributions from leading drug delivery experts, ONdrugDelivery is a must for pharma / biotech industry professionals who need to know what’s going on in drug delivery. Subscribe online today to the print or free digital edition: www.ondrugdelivery.com/subscribe.


    Ophthalmology Times Europe

    Official Media Partner
    http://europe.ophthalmologytimes.com/

    Ophthalmology Times Europe, is a physician-driven media brand that presents cutting-edge advancements from around the world in surgery, clinical diagnosis, drug therapy, and technology to elevate the delivery of progressive eye health from physician to patient.

    Media Partners


    Experimentica

    Supporting Media Partners
    http://www.experimentica.com

    Experimentica Ltd. is a global company and the largest ophthalmic CRO in Northern Europe, striving to provide scientific excellence by relying entirely on in-house expertise. Experimentica Ltd. is headquartered in Kuopio, Finland with offices in Tampere, Finland, Chicago, IL, USA, Shanghai, China, and R&D site in Vilnius, Lithuania. For more information, visit www.experimentica.com.


    eyetube

    Supporting Media Partners
    http://eyetube.net

    Eyetube.net is ophthalmology’s leading source for high-quality, full-narrated ophthalmic surgical videos. The Web site was created by a panel of experts to better educate ophthalmologists through the online archiving and sharing of videos. Our mission is to foster a secure, engaging physician community across all sub-specialties powered by user-generated content, whether it be videos, discussion threads, or blogs.


    ProMed Pharma

    Supporting Media Partners
    http://www.promedpharmallc.com

    ProMed Pharma specializes in the molding of drug-loaded silicones and thermoplastics and leverages this expertise to manufacture long-term implants and combination devices under cGMP. Working with established and early stage companies, we utilize robust manufacturing processes for controlled release of APIs utilizing a variety of materials. From clinical trial materials to commercial products, ProMed supports pharmaceutical and medical device companies developing controlled release formulations including subcutaneous, orthopedic, cardiovacular, and ophthalmic implants, intravaginal rings, and steroid-eluting components. Please visit www.promedpharmallc.com for more details.


    Pharma Journalist

    Supporting Media Partners
    http://www.pharmajournalist.com

    Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry. Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry. Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.


    Pharma network magazine

    Supporting Media Partners
    https://www.pharmanetwork.digital

    PHARMAnetwork is a company specialized in publishing for the pharmaceutical industry. PHARMAnetwork has developed publications for CMO, CDMO and professionals working in the life sciences. PHARMAnetwork designs specialized studies for pharmaceutical companies, contract service providers and investment firms. PHARMAnetwork magazine covers, every aspect of pharmaceutical value chain, the change and developments in the intersection between pharmaceutical industry and outsourcing industry. We perform interviews and write articles whose thematic strategies, organizations, mergers and acquisitions, regulatory, innovation in the pharmaceutical development and contract manufacturing. https://www.pharmanetwork.digital


    Gene Therapy Net

    Supporting Media Partners
    http://www.genetherapynet.com

    Gene Therapy Net is the information resource for basic and clinical research in gene therapy, and the site serves as a network in the exchange of gene therapy information and breaking news items. Visitors can keep track of the latest scientific papers, conference announcements, gene therapy jobs, regulations and guidelines

    Media Partners


    Drug Discovery Today

    Supporters
    http://www.drugdiscoverytoday.com/

    Drug Discovery Today covers the whole of the preclinical drug discovery process. The reviews are cutting edge, written by experts in their respective fields and cover all aspects of drug discovery from genomic and proteomic approaches, computational drug design, medicinal chemistry and the translation of these sciences to therapies.


    Farmavita

    Supporters
    https://farmavitar.com

    FarmavitaR+ is the professional network of experts and service providers. Network is gathering local consultants from 90 countries in Europe, Asia, North America, Latin America, Australia and Africa. Management of international, multi-centre projects is our core competence. FarmavitaR+ is providing solutions related to pharmaceutical, medical device, food supplement and cosmetic products. Scope of services is related to solutions for product development, quality assurance, clinical trials, product registration, portfolio analysis, lifecycle management, vigilance/risk management, pricing/reimbursing, market access and promotional compliance. FarmavitaR+ is brand name of Farmavita Regulanet Ltd. Visit https://farmavitar.com for more information. Outsource anything you can think of!


    IPI

    Supporters
    http://www.ipimediaworld.com

    IPI – International Pharmaceutical Industry Established by professionals with over 30 years experience in the Pharmaceutical and Life sciences publishing sectors. We have identified the needs of these dynamic industries, and have listened carefully to our readers and advertisers. With strong collaboration between Pharmaceutical and Life sciences Industry Associations we have created a global distribution network. We give you a promise to become a reliable extension of your marketing and communication arm. If necessary we will integrate our expertise with your needs. Incorporating new and innovative communication methods we will help to highlight your expertise.

    SAVE TO


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    Holiday Inn Kensington Forum

    97 Cromwell Road
    London SW7 4DN
    United Kingdom

    Holiday Inn Kensington Forum

    Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington. 

    The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow. 

    This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel. 

    In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event. 

    So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee. 

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SMi.
    Full details of our privacy policy can be found here https://www.smi-online.co.uk/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smi-online.co.uk.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smi-online.co.uk/opt-out